Trial · NCT04155918
Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
NCT04155918, Phase 2, Completed, Arthrosi Therapeutics
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients. Trials, record NCT04155918. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04155918
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Phase 2a Study of AR882 Alone and in Combination With Febuxostat or Allopurinol in Gout Patients
- NCT number
- NCT04155918
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 30 participants, actual
- Lead sponsor
- Arthrosi Therapeutics
- Conditions
- Gout Patients
- Interventions
- Group 1: AR882 Alone and in Combination with Febuxostat (FBX), Group 2: AR882 Alone and in Combination with Allopurinol (ALLO)
- First posted
- 2019-11-07
- Last updated
- 2020-11-19
Source ClinicalTrials.gov
Registered outcomes24
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | PD profile of AR882 administered alone or in combination with febuxostat | 22 Days | Profile from serum uric acid concentration over time |
| Primary | PD profile of AR882 administered alone or in combination with allopurinol | 22 Days | Profile from serum uric acid concentration over time. |
| Primary | Serum uric acid (sUA) response rate | 22 Days | sUA response rate to achieve sUA \<6, \<5, \<4, and \<3 mg/dL |
| Secondary | Area under the curve (AUC) for plasma AR882 | 22 Days | Profile from plasma in terms of AUC for AR882 |
| Secondary | Time to maximum plasma concentration (Tmax) for AR882 | 22 Days | Profile from plasma in terms of Tmax for AR882 |
| Secondary | Maximum plasma concentration (Cmax) for AR882 | 22 Days | Profile from plasma in terms of Cmax for AR882 |
| Secondary | Apparent terminal half-life (t1/2) for AR882 | 22 Days | Profile from plasma in terms of t1/2 for AR882 |
| Secondary | Amount excreted (Ae) into urine for AR882 | 22 Days | Profile from urine in terms of Ae for AR882 |
| Secondary | Renal clearance (CLr) for AR882 | 22 Days | Profile from urine in terms of CLr for AR882 |
| Secondary | AUC for plasma for febuxostat | 22 Days | Profile from plasma in terms of AUC for febuxostat |
1 to 10 of 24Source ClinicalTrials.gov
See all 24 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04155918
GET https://conductscience.org/api/trials/v1/NCT04155918/registered?page=2